Abstract

Anticoagulation and antiplatelet therapy became a cornerstone of the primary treatment strategy in the case of acute coronary syndrome patients which planned to receive medical treatment or percutaneous coronary intervention. The anticoagulation regimen is unfractionated heparins and low molecular weight heparins enoxaparin. Despite of some debates, enoxaparin has replaced unfractionated heparins recently due to its demonstrated advantages. When we encountered acute coronary syndrome patients without contraindication for enoxaparin, it tends to be administered with no hesitation. However, a few patients treated with enoxaparin could be suffered from bleeding complication. Also, in case of bleeding into the retroperitoneal space, the result can be fatal. We report a patient who developed a fatal retroperitoneal hematoma during enoxaparin treatment for acute coronary syndrome.

• Keywords: Enoxaparin, Acute Coronary Syndrome, Retroperitoneal Hematoma